Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-426-5 | CAS number: 26040-51-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Experimental start date: 18 April 2017 Experimental completion date: 08 August 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
Test material
- Reference substance name:
- Bis(2-ethylhexyl) tetrabromophthalate
- EC Number:
- 247-426-5
- EC Name:
- Bis(2-ethylhexyl) tetrabromophthalate
- Cas Number:
- 26040-51-7
- Molecular formula:
- C24H34Br4O4
- IUPAC Name:
- 1,2-bis(2-ethylhexyl) 3,4,5,6-tetrabromobenzene-1,2-dicarboxylate
- Reference substance name:
- Benzoic acid, 2,3,4,5-tetrabromo-, 2-ethylhexyl ester
- Cas Number:
- 183658-27-7
- Molecular formula:
- C15H18Br4O2
- IUPAC Name:
- Benzoic acid, 2,3,4,5-tetrabromo-, 2-ethylhexyl ester
- Reference substance name:
- bis(2-ethylhexyl) 3,4,5-tribromophthalate
- Molecular formula:
- C24H35Br344
- IUPAC Name:
- bis(2-ethylhexyl) 3,4,5-tribromophthalate
- Reference substance name:
- bis(2-ethylhexyl) 3,4,6-tribromophthalate
- Cas Number:
- 122857-50-5
- Molecular formula:
- C24H35Br3O4
- IUPAC Name:
- bis(2-ethylhexyl) 3,4,6-tribromophthalate
- Test material form:
- liquid
- Details on test material:
- Batch No.: GS16337E71
Constituent 1
impurity 1
impurity 2
impurity 3
- Specific details on test material used for the study:
- Storage Conditions: Room temperature, in the dark
Expiry Date: 12 May 2018
Method
- Target gene:
- Histidine locus in S. typhimurium and tryptophan locus in E.coli.
Species / strain
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver homogenate metabolizing system (10% liver S9 in standard co factors)
- Test concentrations with justification for top dose:
- Experiment 1 - Plate Incorporation Method
The maximum concentration was 5000 µg/plate (the maximum recommended dose level).
Eight concentrations of the test item (1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate) were tested
Experiment 2 – Pre-Incubation Method
The dose range used for Experiment 2 was determined by the results of Experiment 1 and was 15 to 5000 µg/plate.
Six concentrations of the test item (15, 50, 150, 500, 1500 and 5000 µg/plate) were tested - Vehicle / solvent:
- The test item was immiscible in sterile distilled water and dimethyl sulphoxide at 50 mg/mL but was fully miscible in acetone at 100 mg/mL in solubility checks performed in–house. Acetone was selected as the vehicle. The homogeneity and stability was confirmed for the test item as outlined in the Study Plan in acetone formulations at nominal concentrations of 0.1 and 200 mg/mL.
Furthermore, to support this, homogeneity and stability were previously confirmed in Harlan CCR study 1502500 for concentrations of 0.05 and 500 mg/mL.
Controlsopen allclose all
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- acetone
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 2 µg/plate for WP2uvrA, 3 µg/plate for TA100, 5 µg/plate for TA1535
- Positive control substance:
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- acetone
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 80 µg/plate for TA1537
- Positive control substance:
- 9-aminoacridine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- acetone
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.2 µg/plate for TA98
- Positive control substance:
- other: 4-Nitroquinoline-1-oxide
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- acetone
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 1 µg/plate for TA100, 2 µg/plate for TA1535 and TA1537, 10 µg/plate WP2uvrA
- Positive control substance:
- other: 2-Aminoanthracene
- Remarks:
- Presence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- acetone
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 5 µg/plate for TA98
- Positive control substance:
- benzo(a)pyrene
- Remarks:
- Presence of S9-mix
- Details on test system and experimental conditions:
- Experimental Design and Study Conduct
Test Item Preparation and Analysis
The test item was accurately weighed and approximate half-log dilutions prepared in acetone by mixing on a vortex mixer on the day of each experiment. No correction was made for purity. Acetone is toxic to the bacterial cells at 0.1 mL (100 µL) after employing the pre-incubation modification; therefore all of the formulations for Experiment 2 were prepared at concentrations two times greater than required on Vogel-Bonner agar plates. To compensate, each formulation was dosed using 0.05 mL (50 µL) aliquots (Maron et al., 1981). All formulations were used within four hours of preparation. Prior to use, the solvent was dried to remove water using molecular sieves i.e. 2 mm sodium alumino silicate pellets with a nominal pore diameter of 4 x 10^-4 microns. Analysis was carried out in Experiment 1 to determine the concentration of the maximum test item formulation (50 mg/mL).
During the Dose Formulation Analysis phase, only the maximum dose level in the first experiment (50 mg/mL) was analyzed; the absence of a Dose Formulation Analysis of a mid and low dose level is considered an exception which is thought not to affect the purpose or integrity of the study.
Test for Mutagenicity: Experiment 1 - Plate Incorporation Method
Eight concentrations of the test item were assayed in triplicate against each tester strain, using the direct plate incorporation method.
Without Metabolic Activation
0.1 mL of the appropriate concentration of test item, solvent vehicle or appropriate positive control was added to 2 mL of molten, trace amino-acid supplemented media containing 0.1 mL of one of the bacterial strain cultures and 0.5 mL of phosphate buffer. These were then mixed and overlayed onto a Vogel Bonner agar plate. Negative (untreated) controls were also performed on the same day as the mutation test. Each concentration of the test item, appropriate positive, vehicle and negative controls, and each bacterial strain, was assayed using triplicate plates.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial culture, 0.5 mL of S9 mix was added to the molten, trace amino-acid supplemented media instead of phosphate buffer.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 ºC for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). Several manual counts were required due to revertant colonies spreading slightly, thus distorting the actual plate count.
Test for Mutagenicity: Experiment 2
As the result of Experiment 1 was deemed negative, Experiment 2 was performed using the pre-incubation method in the presence and absence of metabolic activation.
Six test item dose levels per bacterial strain were selected in the second mutation test in order to achieve both a minimum of four non toxic dose levels and the toxic limit of the test item following the change in test methodology from plate incorporation to pre-incubation.
Without Metabolic Activation
0.1 mL of the appropriate bacterial strain culture, 0.5 mL of phosphate buffer and 0.05 mL of the test item formulation or solvent vehicle or 0.1 mL of appropriate positive control were incubated at 37 ± 3 ºC for 20 minutes (with shaking) prior to addition of 2 mL of molten, trace amino-acid supplemented media and subsequent plating onto Vogel Bonner plates. Negative (untreated) controls were also performed on the same day as the mutation test employing the plate incorporation method. All testing for this experiment was performed in triplicate.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial strain culture, 0.5 mL of S9 mix was added to the tube instead of phosphate buffer, prior to incubation at 37 ± 3 ºC for 20 minutes (with shaking) and addition of molten, trace amino-acid supplemented media. All testing for this experiment was performed in triplicate.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 ºC for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). Due to a hardware failure, Ames study manager and sorcerer system suffered an extended downtime, resulting in manual counts being performed on all of the plates produced for Experiment 2. - Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).
5. Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out of historical range response (Cariello and Piegorsch, 1996)).
A test item will be considered non-mutagenic (negative) in the test system if the above criteria are not met.
Although most experiments will give clear positive or negative results, in some instances the data generated will prohibit making a definite judgment about test item activity. Results of this type will be reported as equivocal. - Statistics:
- Statistical significance was confirmed by using Dunnetts Regression Analysis (* = p < 0.05) for those values that indicate statistically significant increases in the frequency of revertant colonies compared to the concurrent solvent control.
Results and discussion
Test resultsopen allclose all
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Prior to use, the master strains were checked for characteristics, viability and spontaneous reversion rate (all were found to be satisfactory). The amino acid supplemented top agar and the S9-mix used in both experiments was shown to be sterile. The test item formulation was also shown to be sterile. These data are not given in the report.
Results for the negative controls (spontaneous mutation rates) were considered to be acceptable. These data are for concurrent untreated control plates performed on the same day as the Mutation Test.
The vehicle (acetone) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The maximum dose level of the test item in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test (plate incorporation method) and consequently the same maximum dose level was used in the second mutation test. Similarly, there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the second mutation test (pre-incubation method).
A test item precipitate (globular and light in appearance) was noted at 5000 µg/plate, this observation did not prevent the scoring of revertant colonies.
There were no increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1 (plate incorporation method). Similarly, no increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 2 (pre-incubation method).
Any other information on results incl. tables
Spontaneous Mutation Rates (Concurrent Negative Controls)
Experiment 1
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
102 |
|
22 |
|
28 |
|
27 |
|
9 |
|
88 |
(89) |
27 |
(26) |
33 |
(32) |
19 |
(24) |
3 |
(8) |
78 |
|
30 |
|
34 |
|
25 |
|
13 |
|
Experiment 2
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
80 |
|
23 |
|
24 |
|
22 |
|
19 |
|
91 |
(82) |
15 |
(19) |
29 |
(24) |
21 |
(22) |
9 |
(14) |
76 |
|
19 |
|
20 |
|
23 |
|
13 |
|
Test Results: Experiment 1 – Without Metabolic Activation
Test Period |
From: 20 June 2017 |
To: 23 June 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (Acetone) |
95 113 97 |
(102) 9.9# |
24 20 24 |
(23) 2.3 |
36 21 25 |
(27) 7.8 |
23 21 22 |
(22) 1.0 |
8 18 18 |
(15) 5.8 |
||
1.5 µg |
93 87 74 |
(85) 9.7 |
27 30 31 |
(29) 2.1 |
28 33 27 |
(29) 3.2 |
16 25 17 |
(19) 4.9 |
14 12 17 |
(14) 2.5 |
||
5 µg |
63 64 74 |
(67) 6.1 |
29 32 16 |
(26) 8.5 |
33 27 28 |
(29) 3.2 |
21 24 22 |
(22) 1.5 |
11 26 11 |
(16) 8.7 |
||
15 µg |
73 61 76 |
(70) 7.9 |
17 19 21 |
(19) 2.0 |
28 32 27 |
(29) 2.6 |
13 28 27 |
(23) 8.4 |
19 18 20 |
(19) 1.0 |
||
50 µg |
94 71 83 |
(83) 11.5 |
30 21 19 |
(23) 5.9 |
40 17 17 |
(25) 13.3 |
29 15 21 |
(22) 7.0 |
12 13 15 |
(13) 1.5 |
||
150 µg |
64 72 81 |
(72) 8.5 |
21 27 21 |
(23) 3.5 |
28 29 31 |
(29) 1.5 |
13 29 24 |
(22) 8.2 |
11 7 18 |
(12) 5.6 |
||
500 µg |
73 72 63 |
(69) 5.5 |
30 30 16 |
(25) 8.1 |
32 22 22 |
(25) 5.8 |
14 22 12 |
(16) 5.3 |
12 11 16 |
(13) 2.6 |
||
1500 µg |
72 81 81 |
(78) 5.2 |
25 27 25 |
(26) 1.2 |
31 21 37 |
(30) 8.1 |
20 27 23 |
(23) 3.5 |
20 10 14 |
(15) 5.0 |
||
5000 µg |
80 P 73 P 72 P |
(75) 4.4 |
27 P 27 P 25 P |
(26) 1.2 |
28 P 30 P 37 P |
(32) 4.7 |
21 P 21 P 17 P |
(20) 2.3 |
17 P 10 P 14 P |
(14) 3.5 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
509 456 595 |
(520) 70.1 |
531 699 676 |
(635) 91.1 |
752 744 742 |
(746) 5.3 |
241 224 249 |
(238) 12.8 |
118 144 178 |
(147) 30.1 |
|||
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
P Test item precipitate
# Standard deviation
Test Results: Experiment 1 – With Metabolic Activation
Test Period |
From: 20 June 2017 |
To: 23 June 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (Acetone) |
84 92 102 |
(93) 9.0# |
29 21 16 |
(22) 6.6 |
43 38 39 |
(40) 2.6 |
28 22 25 |
(25) 3.0 |
15 17 9 |
(14) 4.2 |
||
1.5 µg |
71 66 67 |
(68) 2.6 |
17 27 27 |
(24) 5.8 |
40 45 33 |
(39) 6.0 |
20 22 25 |
(22) 2.5 |
13 16 15 |
(15) 1.5 |
||
5 µg |
63 66 65 |
(65) 1.5 |
26 15 26 |
(22) 6.4 |
29 37 34 |
(33) 4.0 |
25 18 21 |
(21) 3.5 |
13 10 13 |
(12) 1.7 |
||
15 µg |
67 69 79 |
(72) 6.4 |
29 19 28 |
(25) 5.5 |
49 33 21 |
(34) 14.0 |
21 30 23 |
(25) 4.7 |
15 19 8 |
(14) 5.6 |
||
50 µg |
79 73 73 |
(75) 3.5 |
26 27 12 |
(22) 8.4 |
38 20 32 |
(30) 9.2 |
25 24 21 |
(23) 2.1 |
23 16 5 |
(15) 9.1 |
||
150 µg |
81 76 79 |
(79) 2.5 |
27 19 26 |
(24) 4.4 |
40 31 29 |
(33) 5.9 |
26 23 28 |
(26) 2.5 |
6 8 13 |
(9) 3.6 |
||
500 µg |
79 93 74 |
(82) 9.8 |
26 21 17 |
(21) 4.5 |
49 34 35 |
(39) 8.4 |
26 27 24 |
(26) 1.5 |
14 13 20 |
(16) 3.8 |
||
1500 µg |
91 72 79 |
(81) 9.6 |
28 27 27 |
(27) 0.6 |
44 39 38 |
(40) 3.2 |
28 26 25 |
(26) 1.5 |
7 13 14 |
(11) 3.8 |
||
5000 µg |
71 P 72 P 79 P |
(74) 4.4 |
30 P 29 P 22 P |
(27) 4.4 |
35 P 27 P 32 P |
(31) 4.0 |
31 P 26 P 27 P |
(28) 2.6 |
17 P 13 P 14 P |
(15) 2.1 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
575 620 501 |
(565) 60.1 |
311 208 232 |
(250) 53.9 |
146 167 165 |
(159) 11.6 |
208 165 169 |
(181) 23.8 |
608 621 618 |
(616) 6.8 |
|||
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
P Test item precipitate
# Standard deviation
Test Results: Experiment 2 – Without Metabolic Activation
Test Period |
From: 02 August 2017 |
To: 05 August 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (Acetone) |
83 76 82 |
(80) 3.8# |
13 22 18 |
(18) 4.5 |
25 32 32 |
(30) 4.0 |
25 17 25 |
(22) 4.6 |
18 10 12 |
(13) 4.2 |
||
15 µg |
76 87 72 |
(78) 7.8 |
16 18 24 |
(19) 4.2 |
18 25 37 |
(27) 9.6 |
17 19 24 |
(20) 3.6 |
18 11 9 |
(13) 4.7 |
||
50 µg |
66 77 73 |
(72) 5.6 |
19 15 17 |
(17) 2.0 |
28 35 26 |
(30) 4.7 |
25 21 19 |
(22) 3.1 |
12 13 17 |
(14) 2.6 |
||
150 µg |
71 70 80 |
(74) 5.5 |
19 17 20 |
(19) 1.5 |
32 30 26 |
(29) 3.1 |
22 21 16 |
(20) 3.2 |
13 20 6 |
(13) 7.0 |
||
500 µg |
73 71 74 |
(73) 1.5 |
19 16 12 |
(16) 3.5 |
28 27 27 |
(27) 0.6 |
19 20 21 |
(20) 1.0 |
12 15 12 |
(13) 1.7 |
||
1500 µg |
87 72 81 |
(80) 7.5 |
18 12 22 |
(17) 5.0 |
31 21 24 |
(25) 5.1 |
22 20 17 |
(20) 2.5 |
8 9 19 |
(12) 6.1 |
||
5000 µg |
74 P 75 P 85 P |
(78) 6.1 |
19 P 22 P 22 P |
(21) 1.7 |
24 P 31 P 19 P |
(25) 6.0 |
23 P 18 P 20 P |
(20) 2.5 |
11 P 13 P 17 P |
(14) 3.1 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
594 620 585 |
(600) 18.2 |
1113 1166 932 |
(1070) 122.7 |
1095 1041 941 |
(1026) 78.1 |
240 256 263 |
(253) 11.8 |
174 278 249 |
(234) 53.7 |
|||
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
P Test item precipitate
# Standard deviation
Test Results: Experiment 2 – With Metabolic Activation
Test Period |
From: 02 August 2017 |
To: 05 August 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (Acetone) |
80 83 80 |
(81) 1.7# |
25 21 12 |
(19) 6.7 |
22 29 29 |
(27) 4.0 |
28 20 26 |
(25) 4.2 |
14 10 16 |
(13) 3.1 |
||
15 µg |
80 75 69 |
(75) 5.5 |
15 22 13 |
(17) 4.7 |
21 24 32 |
(26) 5.7 |
30 22 20 |
(24) 5.3 |
16 12 16 |
(15) 2.3 |
||
50 µg |
80 74 70 |
(75) 5.0 |
29 21 11 |
(20) 9.0 |
27 28 29 |
(28) 1.0 |
31 20 28 |
(26) 5.7 |
14 13 9 |
(12) 2.6 |
||
150 µg |
69 85 73 |
(76) 8.3 |
15 20 20 |
(18) 2.9 |
29 24 31 |
(28) 3.6 |
18 30 28 |
(25) 6.4 |
10 14 15 |
(13) 2.6 |
||
500 µg |
78 68 77 |
(74) 5.5 |
23 21 18 |
(21) 2.5 |
28 26 34 |
(29) 4.2 |
25 27 16 |
(23) 5.9 |
13 19 18 |
(17) 3.2 |
||
1500 µg |
73 88 70 |
(77) 9.6 |
14 22 20 |
(19) 4.2 |
22 26 31 |
(26) 4.5 |
26 25 31 |
(27) 3.2 |
13 14 12 |
(13) 1.0 |
||
5000 µg |
87 P 77 P 70 P |
(78) 8.5 |
19 P 17 P 23 P |
(20) 3.1 |
28 P 27 P 29 P |
(28) 1.0 |
19 P 29 P 24 P |
(24) 5.0 |
12 P 18 P 16 P |
(15) 3.1 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
1090 1088 1039 |
(1072) 28.9 |
252 266 247 |
(255) 9.8 |
210 213 239 |
(221) 15.9 |
162 150 144 |
(152) 9.2 |
389 367 286 |
(347) 54.2 |
|||
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
P Test item precipitate
# Standard deviation
Applicant's summary and conclusion
- Conclusions:
- Bis(2-ethylhexyl) tetrabromophthalate (CAS No. 26040-51-7) was considered to be non-mutagenic under the conditions of this test.
- Executive summary:
Introduction
The test method was designed to be compatible with the guidelines for bacterial mutagenicity testing published by the major Japanese Regulatory Authorities including METI, MHLW and MAFF, the OECD Guidelines for Testing of Chemicals No. 471 "Bacterial Reverse Mutation Test", Method B13/14 of Commission Regulation (EC) number 440/2008 of 30 May 2008 and the USA, EPA OCSPP harmonized guideline - Bacterial Reverse Mutation Test.
Methods
Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100 and Escherichia coli strain WP2uvrA were treated with bis(2-ethylhexyl) tetrabromophthalate (CAS No. 26040-51-7) using both the Ames plate incorporation and pre-incubation methods at eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co‑factors). The dose range for Experiment 1 was predetermined and was 1.5 to 5000 mg/plate. The experiment was repeated on a separate day (Experiment 2, pre-incubation method) using fresh cultures of the bacterial strains and fresh test item formulations. The dose range for Experiment 2 was amended, following the results of Experiment 1, and was 15 to 5000 µg/plate. Six test item concentrations were selected in Experiment 2 in order to achieve both four non‑toxic dose levels and the potential toxic limit of the test item following the change in test methodology.
Formulation analysis was carried out in Experiment 1 to determine the concentration of the test item concentration (maximum dose).
Results
The vehicle (acetone) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The maximum dose level of the test item in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test (plate incorporation method) and consequently the same maximum dose level was used in the second mutation test. Similarly, there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the second mutation test (pre-incubation method).
A test item precipitate (globular and light in appearance) was noted at 5000 mg/plate, this observation did not prevent the scoring of revertant colonies.
There were no increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1 (plate incorporation method). Similarly, no increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 2 (pre-incubation method).
Conclusion
Bis(2-ethylhexyl) tetrabromophthalate (CAS No. 26040-51-7)was considered to be non-mutagenic under the conditions of this test.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
